RT Journal Article
SR Electronic
T1 Improved precision oncology question-answering using agentic LLM
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.09.20.24314076
DO 10.1101/2024.09.20.24314076
A1 Das, Rangan
A1 Maheswari, K
A1 Siddiqui, Shaheen
A1 Arora, Nikita
A1 Paul, Ankush
A1 Nanshi, Jeet
A1 Udbalkar, Varun
A1 Sarvade, Apoorva
A1 Chaturvedi, Harsha
A1 Shvartsman, Tammy
A1 Masih, Shet
A1 Thippeswamy, R
A1 Patil, Shekar
A1 Nirni, S S
A1 Garsson, Brian
A1 Bandyopadhyay, Sanghamitra
A1 Maulik, Ujjwal
A1 Farooq, Mohammed
A1 Sengupta, Debarka
YR 2024
UL http://medrxiv.org/content/early/2024/10/05/2024.09.20.24314076.abstract
AB The clinical adoption of Large Language Models (LLMs) in biomedical research has been limited by concerns regarding the quality, accuracy, and reliability of their outputs, particularly in precision oncology, where clinical decision-making demands high precision. Current models, often based on fine-tuned foundational LLMs, are prone to issues such as hallucinations, incoherent reasoning, and loss of context. In this work, we present GeneSilico Copilot, an advanced agent-based architecture that transforms LLMs from simple response synthesizers to clinical reasoning systems. Our approach is centred around a bespoke ReAct agent that orchestrates a suite of specialized tools for asynchronous information retrieval and synthesis. These tools access curated document vector stores containing clinical treatment guidelines, genomic insights, drug information, clinical trials, and breast cancer-specific literature. To leverage large context windows of current LLMs, we implement a hybrid search strategy that prioritizes key information and dynamically integrates summarized content, reducing context fragmentation. Incorporating additional metadata further allows for precise, transparent and evidence-backed reasoning at each step of the thought process. The system ensures that at every stage, the agent can synthesize meaningful, context-aware observations that contribute to a coherent and comprehensive final response that aligns with clinical standards. Evaluations on real-world breast cancer cases show that GeneSilico Copilot significantly improves response accuracy and personalization. This system represents a critical advancement toward making LLMs clinically deployable in precision oncology and has potential applications in broader medical domains requiring complex, data-driven decision-making.Competing Interest StatementA provisional patent has been filed on 10/02/2024 (DW No.: 107881-00009, Serial No.: 63/702,408) describing the agentic framework. All the authors, except for SB are GeneSilico, Inc. employees/partners.Funding StatementThe entire study is funded by GeneSilico, Inc.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study used openly available human data sources such as Pubmed, PharmGKB, Clinical Trial databases, DrugBank Open Data, and NCCN/ASCO/ESMO.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThis is already mentioned in the Data Availability section of the manuscript.